cleared by

a ghost device

Problem statement

The FDA's 510(k) clearance pathway — used for the large majority of new medical device authorizations (82% of the devices FDA cleared or approved in 2017) — allows devices to reach market by demonstrating "substantial equivalence" to a previously cleared predicate device rather than requiring independent clinical evaluation. Over successive generations, devices accumulate significant changes in technology, materials, and intended use while maintaining a chain of equivalence back to predicates that may be decades old, withdrawn, or even recalled. This "predicate creep" means modern devices can bear little functional resemblance to the original safety baseline, yet they have never undergone independent clinical testing. By FDA's own account, nearly 20% of 510(k)s are cleared based on a predicate more than 10 years old, and documented predicate networks reach back decades — a published analysis of one robotic surgical system traced an ancestry network of 2,618 device instances across 15 product codes, with clearances dating back to 1981.

Why this matters

Roughly 3,000 510(k) clearances are issued annually (3,173 in 2017), covering categories including surgical instruments, cardiovascular devices, and AI/ML-based diagnostic tools. When a device in a predicate chain fails in the field, the safety assumptions propagated through the entire chain are retroactively invalidated, yet downstream devices are not automatically recalled or re-evaluated. The propagation risk is measurable: among 510(k)-cleared devices subject to Class I recalls in 2017–2021, 44.1% had been authorized using predicates that themselves had Class I recall histories, and devices cleared on such predicates were 6.4 times more likely to suffer their own Class I recall (Kadakia et al., JAMA 2023). A 2023 Lancet Digital Health study (Muehlematter & Vokinger) found that more than a third of AI/ML-based devices cleared via 510(k) originated from non-AI/ML predicate devices — meaning the "substantially equivalent" device used an entirely different technology.

What’s been tried and why it hasn’t worked

On September 7, 2023, the FDA issued three draft guidances to strengthen the 510(k) program — covering predicate selection best practices, use of clinical data in 510(k) submissions, and evidentiary expectations for implant devices. However, these remain non-binding draft guidance and do not address the fundamental structural limitation: the 510(k) pathway is designed for incremental change, not for assessing whether cumulative changes have crossed a safety threshold. The predicate-selection draft guidance recommends choosing predicates that were cleared using well-established methods, meet or exceed expected safety and performance, have no unmitigated use- or design-related safety issues, and have no design-related recall — and the FDA has encouraged use of more modern predicates since 2018 — but these are recommendations, not requirements. Devices subject to Class I recalls (the most serious category) can still be used as predicates for new submissions, propagating the safety assumptions of a recalled device into new products — the Kadakia et al. JAMA 2023 study documented descendants cleared while their predicates' safety issues remained unresolved. No mechanism exists to evaluate cumulative technological drift across a predicate chain.

What would unlock progress

A computable "predicate distance" metric — quantifying how far a proposed device has drifted from its oldest predicate in technology, materials, and intended use — could flag submissions where cumulative change exceeds a meaningful threshold. This would require a structured, machine-readable representation of device characteristics at each step in the predicate chain, combined with a decision rule for when clinical data should be required. Adjacent models exist in software dependency tracking and version control systems.

Entry points for student teams

A student team could build a network analysis tool that maps publicly available 510(k) predicate chains from the FDA database, calculates chain length and age, and identifies high-risk chains (those involving recalled predicates, technology-class changes, or extreme predicate age). A more ambitious team could prototype a "predicate distance" scoring algorithm using device classification codes, product codes, and summary documents. Relevant skills include data science, network analysis, regulatory science, and health informatics.